Company: ARTL
Filing Date: 2025-11-17
Form Type: S-1
Source: 0001640334-25-002154
Chunk: 14

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-17
Form: S-1
Chunk 14
---
2025, we entered into the October 2025 Subscription Agreement with the Selling Securityholders named in this prospectus, pursuant to which we issued and sold to the Selling Securityholders, and the Selling Securityholders purchased (by converting all or a portion of the unconverted “Voluntary Conversion” portion of unpaid principal balance and accrued interest due to the Selling Securityholders upon the maturity of the May 2025 Notes): (i) The Notes in an aggregate principal amount of $690,154.69; and (ii) the $3.40 Warrants to purchase an aggregate of 438,182 shares of Common Stock, at an exercise price of $3.40 per share. The sale and issuance of the Notes and $3.40 Warrants closed effective as of October 28, 2025 (the “Closing Date”). The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Notes). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable six months after the Closing Date (the “Maturity Date”). At any time prior to the Maturity Date, all or any portion of the outstanding principal amount of the Notes, together with the accrued and unpaid interest, shall be convertible, in whole or in part, into shares of Common Stock, at a conversion price of $3.40. Each $3.40 Warrant shall be immediately exercisable after issuance for five (5) years. Each $3.40 Warrant will be exercisable by payment of the exercise price in cash or on a cashless basis if at the time of exercise there is no effective resale registration statement and will contain customary anti-dilution provisions (in the case of stock splits, dividends, recapitalizations, mergers  A holder of a Note or $3.40 Warrant may not convert or exercise any such Note or $3.40 Warrant to the extent that such conversion or exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 4.9% of the total number of shares of Common Stock outstanding immediately after giving effect to the conversion or exercise, which percentage may be increased or decreased at the holder’s election not to exceed 19.9%. Pursuant to the Subscription Agreement, the Company agreed (i) to file a registration statement (the “October 2025 Registration Statement”)